In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.
Similar Posts
Weight Loss Product Notifications
Learn about the warnings for weight loss products that contain hidden drugs and other hidden ingredients.FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumorsCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic ActANDA Assessment Program | GDUFA III Performance Goals and Program Enhancements
GDUFA III includes several enhancements to the ANDA assessment process to maximize the efficiency and utility of each assessment cycle. These enhancements aim to reduce the number of assessment cycles and facilitate timely access to safe, effective, high-quality, and affordable generics.Resources for Biomarker Requestors
Information and resources for requestors about FDA’s Biomarker Qualification ProgramFDA In Brief: FDA Issues Draft Guidance to Encourage Cannabis-Related Clinical Research
FDA has issued draft guidance describing the agency’s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis or cannabis-derived compounds.